Murthy, G. S. G., Abaza, Y., Ball, S., Abboud, R., Haddadin, M., Feld, J., Balasubramanian, S. K., Kishtagari, A., Cohen-Nowak, A., Guerra, V., Hawkins, H., Shukla, A., Tan, V., Dulak, D., Tawfiq, R., Dworkin, E., Weiss, J., Feng, A., Gonzalez-Lugo, J., Dhakal, P., Leonard, J., Foucar, C., Badar, T., Shallis, R., Im, A., Patel, S., Lin, C., Patel, A., Winer, E., Atallah, E., Komrokji, R. (2025). Hypomethylating agent with venetoclax versus hypomethylating agent alone in frontline management of myelodysplastic syndrome - impact of subgroups on clinical outcomes. Blood. https://doi.org/10.1182/blood-2025-239